These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 11698761

  • 1. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [Abstract] [Full Text] [Related]

  • 2. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 3. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [Abstract] [Full Text] [Related]

  • 4. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome.
    Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ.
    Transplantation; 2002 Aug 15; 74(3):367-72. PubMed ID: 12177616
    [Abstract] [Full Text] [Related]

  • 5. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 15; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 6. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 7. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
    Soriano-López DP, Alcántar-Fierros JM, Hernández-Plata JA, González-Jorge AL, Velázquez-Ramos S, Flores-Hernández MA, Fuentes V, Castañeda P, Nieto J, Sánchez JL, López B, Valencia-Mayoral P, Varela-Fascinetto G.
    Transplant Proc; 2016 Mar 27; 48(2):654-7. PubMed ID: 27110023
    [Abstract] [Full Text] [Related]

  • 8. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients.
    Kogan DL, Burroughs M, Emre S, Fishbein T, Moscona A, Ramson C, Shneider BL.
    Transplantation; 1999 Apr 15; 67(7):1068-70. PubMed ID: 10221496
    [Abstract] [Full Text] [Related]

  • 9. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients.
    Scheenstra R, Verschuuren EA, de Haan A, Slooff MJ, The TH, Bijleveld CM, Verkade HJ.
    Transpl Infect Dis; 2004 Mar 15; 6(1):15-22. PubMed ID: 15225222
    [Abstract] [Full Text] [Related]

  • 10. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Mar 15; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 11. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 12. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S, Varnous S, Deback C, Golmard JL, Leblond V.
    Am J Transplant; 2014 Apr 15; 14(4):857-66. PubMed ID: 24666832
    [Abstract] [Full Text] [Related]

  • 13. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM.
    Transplantation; 2002 May 27; 73(10):1603-10. PubMed ID: 12042647
    [Abstract] [Full Text] [Related]

  • 14. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun 27; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.
    Transplantation; 1999 Oct 15; 68(7):997-1003. PubMed ID: 10532541
    [Abstract] [Full Text] [Related]

  • 16. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr 15; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
    Kullberg-Lindh C, Saalman R, Olausson M, Herlenius G, Lindh M.
    Pediatr Transplant; 2017 Aug 15; 21(5):. PubMed ID: 28039929
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus and posttransplant lymphoproliferative disease.
    Holmes R.
    J Pediatr Gastroenterol Nutr; 2001 Oct 15; 33(4):442-4. PubMed ID: 11698760
    [No Abstract] [Full Text] [Related]

  • 19. Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation.
    Jang JY, Kim KM, Lee YJ, Lee SG, Chi HS.
    Transplant Proc; 2008 Oct 15; 40(8):2546-8. PubMed ID: 18929796
    [Abstract] [Full Text] [Related]

  • 20. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 15; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.